IMR Press / EJGO / Volume 24 / Issue 2 / pii/2003141

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research

Efficacy of gerncitabine in heavily pretreated advanced ovarian cancer patients

Show Less
1 Departments of Obstetrics and Gynecology, Universities, Turkey
2 Departments of Obstetrics and Gynecology, Universities, Turkey
3 Departments of Osmangazi-Eski?ehir, Universities, Turkey
4 Departments of Akdeniz-Antalya, Universities, Turkey
5 Departments of ?ukurova-Adana, Universities, Turkey
Eur. J. Gynaecol. Oncol. 2003, 24(2), 169–170;
Published: 10 April 2003

Single agent gemcitabine was used in recurrent epithelial ovarian cancer patients after standard treatment with debulking surgery and platin-paclitaxel based chemotherapy. Response rates and toxicity results were evaluated retrospectively. Gemcitabine was given in 1000 mg/m2 intravenous infusion over 30 minutes at 1, 8, 15 days of every 28 days. Clinical response was evaluated with clini­cal findings, serum CA 125 levels, and computerized tomography. Twenty-two patients - ten as second-line, 11 as third-line, and one as fourth line - received gemcitabine. Seven patients received six courses, nine cases three, five cases two and one case one course of treatment. There were four (18.2%) partial and two (9.1 %) complete responses with an overall response rate of 27.3%. Stable disease was also observed in three more cases. The progression-free interval was found to be a median of three months. Grade 3-4 neutropenia was seen in two (9.1 %) and grade 3-4 thrombocytopenia was seen in four (18.2%) cases. Pancytopenia was obser­ved in one (4.5%) patient. There was no grade 3-4 non-hematological toxicity. Antitumoral activity is encouraging in heavily pretreated ovarian cancer patients. A short progression-free interval is noticeable in responding cases. Toxicity is mainly hematologic and moderate.

Ovarian cancer
Back to top